Cantor Fitzgerald reiterates Lemonade stock Overweight rating at $92 By Investing.com

Cantor Fitzgerald reiterated an Overweight rating on Lemonade and kept a $92 price target, implying meaningful upside from the current $56.52 share price. The note cited improving operating momentum, an expected investor day later this year, and a move to positive EBITDA in Q4 as key catalysts. Recent Q1 2026 results also beat expectations, with EPS of -$0.47 versus -$0.57 consensus and revenue of $258 million versus $251.5 million expected.

Analysis

The market is still pricing LMND like a story stock, but the operating mix is moving closer to an insurance compounding model: improving loss ratio, rising gross profit, and a path to EBITDA breakeven reduce the probability of repeated equity dilution. The key second-order effect is that as the shareholder base shifts toward insurance investors, the stock should become less reflexive to AI headline risk and more sensitive to underwriting discipline and capital efficiency, which typically supports a rerating if execution stays consistent over the next 2-3 quarters.

What the market may be missing is that “AI disruption” cuts both ways. For incumbents, AI is a cost and margin threat; for LMND, it is a distribution and expense-ratio lever, so the company can plausibly widen the moat by harvesting data and automating low-value claims work faster than legacy carriers can replatform. If management delivers an investor day that frames this as an insurance technology operating system rather than a consumer app, the multiple could expand before the next earnings cycle.

The biggest risk is not operational slippage, but a sentiment reversal if the company fails to hit the promised EBITDA inflection or if cat-losses/margin normalization cause the loss ratio to stall for even one quarter. Over the next 30-90 days, the stock likely trades on credibility around the path to profitability; over 6-12 months, the debate shifts to whether this can sustain premium growth without re-accelerating acquisition spend. The current setup is attractive only if investors are willing to underwrite a few quarters of noisy execution in exchange for a potentially durable re-rating.

Contrarian view: the rally may not be about fundamentals alone, but about investors covering a crowded skepticism trade after the stock’s prior derating. If the company proves it can generate positive EBITDA without sacrificing growth, the move higher can be self-reinforcing because it broadens the holder base into fundamentally-oriented funds that were previously uninvestable. That makes the risk/reward asymmetric into the next catalyst window, but only if management avoids overpromising on the timeline.

Key Decisions for Investors

• Go long LMND into the next 1-2 earnings prints with a 6-9 month horizon; the asymmetry is driven by a credible EBITDA inflection and possible multiple expansion from low-quality retail ownership to insurance-focused holders.
• Buy LMND Jan-2027 calls or call spreads to express the rerating thesis with defined downside; the catalyst stack is investor day plus profitability inflection, and options reduce risk if underwriting noise delays the inflection by a quarter or two.
• Pair trade: long LMND / short a diversified property-casualty insurer ETF or mature carrier basket over 3-6 months if you want to isolate re-rating from insurance-technology execution; the long leg benefits from improving margins, while the short leg hedges sector beta.
• Trim or avoid chasing above recent highs if the stock gaps on sentiment rather than guidance; the better entry is after any post-earnings volatility that does not break the EBITDA trajectory.
• Set a hard risk stop if gross loss ratio stalls for two consecutive quarters or if management backpedals on positive EBITDA timing; in that case, the thesis shifts from rerating to value trap.